Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004736 · ClinicalTrials.gov registry record · Phase 1
Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00004736 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 44 participants.
The verdict
NCT00004736, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a type of anti-HIV therapy called HAART is effective in lowering levels of HIV and boosting the immune system in HIV-infected patients with tuberculosis (TB). HIV-infected patients with TB have higher levels of HIV and lower CD4 cell counts (cells in the body that fight infection) than HIV-infected patients without TB. HAART has been effective in reducing HIV levels and increasing CD4 cells in patients without TB. However, its effects in HIV-infected patients with TB are unknown.
Interventions
- DRUG Lamivudine
- DRUG Pyrazinamide
- DRUG Nelfinavir mesylate
- DRUG Isoniazid
- DRUG Ethambutol hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004736
The ClinicalTrials.gov registry entry for NCT00004736 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Lamivudine is the first listed.
NCT00004736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004736 about?
NCT00004736 is a clinical study titled "Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis". The purpose of this study is to see if a type of anti-HIV therapy called HAART is effective in lowering levels of HIV and boosting the immune system in HIV-infected patients with tuberculosis (TB). HIV-infected patients with TB have higher levels of HIV and lower CD4 cell counts (cells in the body ...
What is the current status of trial NCT00004736?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants.
What interventions are being tested in trial NCT00004736?
The interventions under investigation include: Lamivudine (DRUG), Pyrazinamide (DRUG), Nelfinavir mesylate (DRUG), Isoniazid (DRUG), Ethambutol hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00004736?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.